GE MEDICAL SYSTEMS

The global precision medicine market was valued at USD 102.17 billion in 2024, expected to reach USD 470.53 billion by 2034, growing at a CAGR of 16.5%. Precision medicine involves personalized treatments based on genetic, environmental, and behavioral profiles. Key technologies include next-generation sequencing and bioinformatics. The U.S. leads with the NIH's 'All of Us Research Program' and collaborations like AstraZeneca's cancer research. AI tools like Tempus and Foundation Medicine enhance genomic analysis. Potential benefits include improved patient privacy, new data tools, and better FDA oversight. North America dominates the market, with Asia-Pacific expected to grow fastest due to strategic collaborations and government standards.

AI in pharma addresses R&D costs, supply chain complexity, and data management by accelerating drug development, automating compliance, managing large datasets, and optimizing clinical trials. Swiss startup Risklick uses AI to streamline clinical trial protocols and integrate historical data. As AI evolves, stakeholders must integrate these innovations to optimize research, enhance data-driven decisions, and meet patient needs.

The 'Apoptosis - Global Strategic Business Report' projects the global market to grow from $5.4B in 2023 to $7.4B by 2030 at a CAGR of 4.6%. Factors driving growth include advances in molecular biology, improved imaging technologies, AI integration, personalized medicine, and increased research in neurodegenerative diseases. Key segments like Apoptosis Assay Kits and Reagents are expected to grow significantly, with the U.S. and China leading regional growth.

GE HealthCare submits FDA application for CleaRecon DL, an AI-based 3D reconstruction technology for improving CBCT image quality on the Allia IGS platform, to be showcased at RSNA conference in Chicago.

GE Healthcare to acquire remaining 50% stake in Tokyo-based radiopharmaceutical firm Nihon Medi-Physics from Sumitomo Chemical, strengthening its precision care strategy and presence in Japan's $7 billion imaging market. NMP's products include Vizamyl, DaTscan, and Myoview, and the acquisition is expected to close in early 2025.

The global Brain Tumor Diagnosis and Treatment market, valued at $1.5B in 2023, is projected to reach $2B by 2030, growing at a CAGR of 4.3%. Primary and Secondary segments are expected to reach $1.3B and grow at 4.1% and 4.8% CAGR, respectively. Key regions include the U.S., China, Japan, Canada, Germany, and Asia-Pacific. Leading companies profiled are AstraZeneca PLC, Carestream Health, Inc., and GE Healthcare.

GE HealthCare unveils Aurora SPECT/CT, a dual-head system enhancing diagnostic capabilities and patient care with advanced features and AI-powered solutions, unveiled at RSNA 2024.

AI in precision medicine market growth driven by drug discovery, diagnostics, and therapeutics. AI tools enable personalized healthcare via advanced data analytics, using models like CNNs, RNNs, GANs, and GNNs. Market segmented into oncology, rare diseases, infectious diseases, neurology, cardiology, hematology, and others, with neurology expected to grow fastest. Drug discovery & development dominates the market due to AI's ability to analyze complex data and speed up targeted therapy discovery. Major players include NVIDIA, Google, Microsoft, IBM, and others, adopting strategies like acquisitions and collaborations to strengthen market presence.

The global Apoptosis market is projected to grow from $5.4B in 2023 to $7.4B by 2030, driven by advances in molecular biology, AI integration, and personalized medicine. Key segments like Apoptosis Assay Kits and Reagents are expected to grow significantly, with the U.S. and China leading regional markets.